Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 221

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens

Open access
Nagpal, Kunal, Foote, Davis, Tan, Fraser, Liu, Yun, Chen, Po-Hsuan Cameron, Steiner, David F., Manoj, Naren, Olson, Niels, Smith, Jenny L., Mohtashamian, Arash, Peterson, Brandon, Amin, Mahul B., Evans, Andrew J., Sweet, Joan W., Cheung, Carol, van der Kwast, Theodorus, Sangoi, Ankur R., Zhou, Ming, Allan, Robert, Humphrey, Peter A., Hipp, Jason D., Gadepalli, Krishna, Corrado, Greg S., Peng, Lily H., Stumpe, Martin C., Mermel, Craig H. · 2020 · JAMA Oncology

Abstract

Importance: For prostate cancer, Gleason grading of the biopsy specimen plays a pivotal role in determining case management. However, Gleason grading is associated with substantial interobserver variability, resulting in a need for decision support tools to improve the reproducibility of Gleason grading in routine clinical practice. Objective: To evaluate the ability of a deep learning system (DLS) to grade diagnostic prostate biopsy specimens. Design, Setting, and Participants: The DLS was evaluated using 752 deidentified digitized images of formalin-fixed paraffin-embedded prostate needle core biopsy specimens obtained from 3 institutions in the United States, including 1 institution not used for DLS development. To obtain the Gleason grade group (GG), each specimen was first reviewed by 2 expert urologic subspecialists from a multi-institutional panel of 6 individuals (years of experience: mean, 25 years; range, 18-34 years). A third subspecialist reviewed discordant cases to arrive at a majority opinion. To reduce diagnostic uncertainty, all subspecialists had access to an immunohistochemical-stained section and 3 histologic sections for every biopsied specimen. Their review was conducted from December 2018 to June 2019. Main Outcomes and Measures: The frequency of the exact agreement of the DLS with the majority opinion of the subspecialists in categorizing each tumor-containing specimen as 1 of 5 categories: nontumor, GG1, GG2, GG3, or GG4-5. For comparison, the rate of agreement of 19 general pathologists' opinions with the subspecialists' majority opinions was also evaluated. Results: For grading tumor-containing biopsy specimens in the validation set (n = 498), the rate of agreement with subspecialists was significantly higher for the DLS (71.7%; 95% CI, 67.9%-75.3%) than for general pathologists (58.0%; 95% CI, 54.5%-61.4%) (P < .001). In subanalyses of biopsy specimens from an external validation set (n = 322), the Gleason grading performance of the DLS remained similar. For distinguishing nontumor from tumor-containing biopsy specimens (n = 752), the rate of agreement with subspecialists was 94.3% (95% CI, 92.4%-95.9%) for the DLS and similar at 94.7% (95% CI, 92.8%-96.3%) for general pathologists (P = .58). Conclusions and Relevance: In this study, the DLS showed higher proficiency than general pathologists at Gleason grading prostate needle core biopsy specimens and generalized to an independent institution. Future research is necessary to evaluate the potential utility of using the DLS as a decision support tool in clinical workflows and to improve the quality of prostate cancer grading for therapy decisions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2020.2485

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 221

Metadata

Authors
Nagpal, K., Foote, D., Tan, F., Liu, Y., Chen, P.-H. C., Steiner, D. F., Manoj, N., Olson, N., Smith, J. L., Mohtashamian, A., Peterson, B., Amin, M. B., Evans, A. J., Sweet, J. W., Cheung, C., van der Kwast, T., Sangoi, A. R., Zhou, M., Allan, R., Humphrey, P. A., Hipp, J. D., Gadepalli, K., Corrado, G. S., Peng, L. H., Stumpe, M. C., & Mermel, C. H.
Venue
JAMA Oncology
Published
2020-09-01
Volume
6
Issue
9
Pages
1372
ISSN
2374-2437 (ISSN-L)
OpenAlex
W3044088237
Cited by
221
References
6
FWCI
12.22
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens. https://app.cochat.ai/papers/10.1001/jamaoncol.2020.2485
The paper
Nagpal, K., Foote, D., Tan, F., Liu, Y., Chen, P.-H. C., Steiner, D. F., Manoj, N., Olson, N., Smith, J. L., Mohtashamian, A., Peterson, B., Amin, M. B., Evans, A. J., Sweet, J. W., Cheung, C., van der Kwast, T., Sangoi, A. R., Zhou, M., Allan, R., . . . Mermel, C. H. (2020). Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2020.2485

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.